Gt biopharma presents preclinical data demonstrating second-generation cd19 targeting tri-specific killer engager (trike®) driving robust nk cell function against b cell malignancies at eha 2022 congress

Brisbane, calif., june 10, 2022 (globe newswire) -- gt biopharma, inc. (“the company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary tri-specific natural killer (nk) cell engager, trike® protein biologic technology platform, announced today, preclinical data in chronic lymphocytic leukemia (“cll”) to be presented at the european hematology association (eha) 2022 congress. the poster presentation titled, “second-generation cd19 targeting tri-specific killer engager drives robust nk cell function against b cell malignancies,” presented by dr. jeff miller's laboratory, university of minnesota.
GTBP Ratings Summary
GTBP Quant Ranking